<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="378">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156229</url>
  </required_header>
  <id_info>
    <org_study_id>CDK-003-101</org_study_id>
    <nct_id>NCT05156229</nct_id>
  </id_info>
  <brief_title>A PHASE 1, DOSE ESCALATION STUDY OF CDK-003 (exoIL-12) IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)</brief_title>
  <acronym>Part B</acronym>
  <official_title>A Phase 1, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intralesionally Administered CDK-003 in Patient-participants With Cutaneous T-cell Lymphoma (CTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Codiak BioSciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Codiak BioSciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, dose escalation study to assess the safety, tolerability, pharmacokinetic&#xD;
      and pharmacodynamic effects of CDK-003. The study is performed in two parts: Part A is a&#xD;
      randomized, double-blind, placebo-controlled, single ascending dose study of CDK-003 in&#xD;
      healthy adult male participants, and Part B is a single arm, open-label, multiple ascending&#xD;
      dose in patient-participants with CTCL. Dose escalation in the study will only occur after&#xD;
      satisfactory review of all available predefined data by the Safety Review Committee. Part A&#xD;
      is complete and this entry describes Part B only.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2021</start_date>
  <completion_date type="Anticipated">January 13, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome</measure>
    <time_frame>up to 2 years</time_frame>
    <description>To determine the safety, tolerability, and DLTs of CDK-003 monotherapy following multiple ascending dose escalation in patient-participants with CTCL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcome</measure>
    <time_frame>up to 2 years</time_frame>
    <description>To identify a recommended phase 2 dose (RP2D) for CDK-003 monotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>up to 2 years</time_frame>
    <description>To evaluate the preliminary anti-tumor activity of CDK-003 monotherapy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Outcome</measure>
    <time_frame>up to 2 years</time_frame>
    <description>To evaluate potential pharmacodynamic biomarkers associated with treatment with CDK-003 monotherapy that may correlate with any anti-tumour effect.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cutaneous T-cell Lymphoma (CTCL)</condition>
  <arm_group>
    <arm_group_label>CDK-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CDK-003</intervention_name>
    <description>CDK-003 administered Intralesionally</description>
    <arm_group_label>CDK-003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed CTCL as per Olsen et al, 2011 or per algorithm for diagnosis&#xD;
             of early MF as per Pimpinelli et al, 2005.&#xD;
&#xD;
          2. Patient-participants with Stage IA-IIB CTCL (MF) with injectable lesions (patches,&#xD;
             plaques, or tumors), who have relapsed or refractory disease following at least 1&#xD;
             prior standard treatment. Patient-participants who are unsuitable to receive standard&#xD;
             treatment or who have declined standard treatment are also eligible.&#xD;
&#xD;
          3. Patient-participants must have ≥ 1 treatable/measurable lesion(s) for injection as per&#xD;
             Olsen criteria.&#xD;
&#xD;
          4. Understands and is able to comply with the study requirements and has signed the&#xD;
             informed consent form.&#xD;
&#xD;
          5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          6. Life expectancy of at least 6 months.&#xD;
&#xD;
          7. Age 18 years or older at the time of signing the informed consent form.&#xD;
&#xD;
          8. Acceptable liver function:&#xD;
&#xD;
               1. Bilirubin equal 1.5x ULN.&#xD;
&#xD;
               2. AST (SGOT), ALT (SGPT) equal 3.0x ULN.&#xD;
&#xD;
          9. Acceptable renal function:&#xD;
&#xD;
             a. Serum creatinine ≤ 1.5x ULN.&#xD;
&#xD;
         10. Acceptable hematologic status:&#xD;
&#xD;
               1. Absolute neutrophil count - 1500 cells/mm3&#xD;
&#xD;
               2. Platelet count - 100,000 /mm3&#xD;
&#xD;
               3. Hemoglobin - 9 g/dL.&#xD;
&#xD;
         11. Acceptable coagulation status: international normalized ratio ≤ 1.5 ULN.&#xD;
             Patient-participants on therapeutic doses of vitamin K antagonists (eg, warfarin) or&#xD;
             direct oral anticoagulants (eg, direct thrombin or direct factor Xa inhibitors) are&#xD;
             not eligible.&#xD;
&#xD;
             Anticoagulation with low molecular weight heparins is permitted.&#xD;
&#xD;
         12. Women of child-producing potential agree to use highly effective contraceptive methods&#xD;
             (see Appendix C for details) for one complete menstrual cycle (or at least 30 days)&#xD;
             prior to the first dose of CDK-003 until 6 months following the last dose of CDK-003,&#xD;
             and avoid egg donation from the time of the first dose of CDK-003 until 6 months&#xD;
             following the last dose of CDK-003. A female participant is considered to be of&#xD;
             child-producing potential unless she:&#xD;
&#xD;
               1. has had a hysterectomy or bilateral oophorectomy or&#xD;
&#xD;
               2. is age ≥ 60 years and is amenorrhoeic or&#xD;
&#xD;
               3. is age &lt; 60 years and has been amenorrhoeic for ≥ 12 months (including no&#xD;
                  irregular menses or spotting) in the absence of any medication which induces a&#xD;
                  menopausal state and has documented ovarian failure by serum estradiol and&#xD;
                  follicle-stimulating hormone levels within the institutional laboratory&#xD;
                  postmenopausal range).&#xD;
&#xD;
         13. A negative pregnancy test (if a woman of child-producing potential) within 72 hours&#xD;
             prior to the first dose of CDK-003.&#xD;
&#xD;
         14. Men of child-producing potential agree to use highly effective contraceptive methods&#xD;
             and avoid sperm donation from the time of the first dose of CDK-003 until 6 months&#xD;
             following the last dose. Male patient-participants must use a condom when engaged in&#xD;
             intercourse during the study and for 6 months after the last dose of study drug.&#xD;
&#xD;
             A man is considered to be of child-producing potential unless he has had a bilateral&#xD;
             vasectomy with documented aspermia or a bilateral orchiectomy.&#xD;
&#xD;
         15. Patient-participant agrees to have a pre-treatment tumor biopsy during the Screening&#xD;
             Period, and 2 on-treatment tumor biopsies of the same lesion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient-participants with CTCL disease involving N3 nodes.&#xD;
&#xD;
          2. Clinically significant ongoing AEs that have not returned to baseline or to Grade 1&#xD;
             National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)&#xD;
             v5.0 during the Screening Period.&#xD;
&#xD;
          3. Received nitrogen mustard, PUVA, narrow band UVB light therapy, carmustine (BCNU),&#xD;
             other systemic therapies, radiation therapy or investigational agents for CTCL within&#xD;
             21 days of Day 1.&#xD;
&#xD;
          4. Received systemic corticosteroids within 28 days of Day 1.&#xD;
&#xD;
          5. Use of topical corticosteroids on any of the target lesions for CDK-003 injection or&#xD;
             non-injected target lesion within 28 days of Day 1. Topical corticosteroid use is&#xD;
             permitted for non-target lesions.&#xD;
&#xD;
          6. Major surgery within 2 months or minor surgery (excluding tumor biopsies) within 14&#xD;
             day prior to Day 1.&#xD;
&#xD;
          7. Clinically significant cardiovascular disease including but not limited to myocardial&#xD;
             infarction or stroke within the past 6 months prior to Day 1, New York Heart&#xD;
             Association Class III or IV heart failure, uncontrolled arrhythmia, or severe aortic&#xD;
             stenosis. Sponsor approval of patient-participants with an arrhythmia is required.&#xD;
&#xD;
          8. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic&#xD;
             therapy.&#xD;
&#xD;
             Prophylactic antibiotics are acceptable.&#xD;
&#xD;
          9. Prior organ or stem cell transplant.&#xD;
&#xD;
         10. Primary immune deficiency.&#xD;
&#xD;
         11. Pregnant or nursing women.&#xD;
&#xD;
         12. Positive test for HBsAg, HCV Ab, or HIV Ab during the Screening Period.&#xD;
&#xD;
         13. Unwillingness or inability to comply with procedures required in this protocol.&#xD;
&#xD;
         14. Serious non-malignant disease (e.g., liver failure, ongoing infection requiring&#xD;
             intravenous treatment, psychological illness, autoimmune disease including but not&#xD;
             limited to inflammatory bowel disease, or other conditions) or social situations that,&#xD;
             in the opinion of the Investigator and/or the Sponsor, could compromise protocol&#xD;
             objectives or patient participant safety or the ability of the patient-participant to&#xD;
             comply with the protocol.&#xD;
&#xD;
         15. History of another malignancy, unless potentially curative treatment has been&#xD;
             performed. Sponsor approval is required. Patient-participants with early stage&#xD;
             prostate cancer on active surveillance may be enrolled with Sponsor approval.&#xD;
&#xD;
         16. Currently receiving any other anti-cancer or investigational agent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Scarisbrick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Birmingham NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katura Fetterson</last_name>
    <phone>(617) 949-4221</phone>
    <email>clinicaltrials@codiakbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julia Scarisbrick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre Haematology</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cowan</last_name>
    </contact>
    <investigator>
      <last_name>Pamela McKay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guys Hospital/ Guy's Cancer Centre</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sophie Papa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Cowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sophie Weatherhead, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

